Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients

Phase 2

Recruiting

Conditions: Hypertension

Interventions: Other: Saline
Drug: QCZ484

First Posted Date: 2025-03-05

Last Posted Date: 2025-06-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 380

Registration Number: NCT06857955

Locations: 🇺🇸
SEC Clinical Research LLC, Andalusia, Alabama, United States
🇺🇸
Synexus Clinical Research US Inc, Richfield, Minnesota, United States
🇺🇸
NICRs Research Center, Garden Grove, California, United States

and more 34 locations

Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

Phase 3

Not yet recruiting

Conditions: Kidney Diseases
Kidney Diseases, Chronic
Urological Diseases
Glomerulonephritis
Glomerular Disease
Glomerulonephritis, IGA
Glomerulopathy
Immunoglobulin Disease

Interventions: Drug: zigakibart

First Posted Date: 2025-03-05

Last Posted Date: 2025-07-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 223

Registration Number: NCT06858319

Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia

Recruiting

Conditions: Atherosclerotic Cardiovascular Disease

Interventions: Drug: Atorvastatin
Drug: Simvastatin
Drug: Rozuvastatin
Drug: Ezetimibe
Drug: Niacin
Drug: Ciprofibrate
Drug: Fenofibrate
Drug: Bezafibrate
Drug: Evolocumab
Drug: Alirocumab
Drug: Inclisiran

First Posted Date: 2025-03-05

Last Posted Date: 2025-06-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 2382

Registration Number: NCT06858332

Locations: 🇷🇺
Novartis Investigative Site, Yakutsk, Russian Federation

A Canadian Study of Persistence on Ofatumumab Using Patient Support Program Data

Completed

Conditions: Multiple Sclerosis, Relapsing-Remitting

First Posted Date: 2025-03-03

Last Posted Date: 2025-03-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 5448

Registration Number: NCT06854341

Locations: 🇺🇸
Novartis, East Hanover, New Jersey, United States

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

Phase 3

Not yet recruiting

Conditions: Prostate Cancer

Interventions: Drug: AAA817
Drug: ARPI
Drug: Standard of Care

First Posted Date: 2025-03-03

Last Posted Date: 2025-05-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 605

Registration Number: NCT06855277

Clinical Outcomes of C3 Glomerulopathy and IC-MPGN in Russia: Hybrid Retrospective - Prospective Study

Not yet recruiting

Conditions: Kidney Diseases

First Posted Date: 2025-02-28

Last Posted Date: 2025-02-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 100

Registration Number: NCT06851845

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Phase 3

Not yet recruiting

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: Remibrutinib oral treatment
Drug: Ocrelizumab

First Posted Date: 2025-02-26

Last Posted Date: 2025-04-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 360

Registration Number: NCT06846281

Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy

Phase 2

Active, not recruiting

Conditions: IgA Nephropathy
Immunoglobulin A Nephropathy

Interventions: Drug: Atrasentan
Drug: Placebo

First Posted Date: 2025-02-24

Last Posted Date: 2025-02-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 54

Registration Number: NCT06841094

Locations: 🇺🇸
University of Alabama at Birmingham (UAB) - The Kirklin Clinic (TKC) - Nephrology Clinic, Birmingham, Alabama, United States
🇺🇸
Fides Clinical Research, Atlanta, Georgia, United States
🇺🇸
NANI Research, Oak Brook, Illinois, United States

and more 27 locations

Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa

Phase 3

Recruiting

Conditions: Hidradenitis Suppurativa

Interventions: Drug: Remibrutinib Dose A
Drug: Remibrutinib Dose B
Drug: Placebo 1
Drug: Placebo 2

First Posted Date: 2025-02-21

Last Posted Date: 2025-07-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 555

Registration Number: NCT06840392

Locations: 🇵🇷
Alma Cruz-Santana Private Practice, Carolina, Puerto Rico
🇺🇸
Total Skin and Beauty Dermatology Center PC, Birmingham, Alabama, United States
🇺🇸
CTT Research, Gilbert, Arizona, United States

and more 30 locations

Ilaris NIS in Korea

Not yet recruiting

Conditions: Hereditary Periodic Fever Syndromes
Colchicine Resistance Familial Mediterranean Fever (crFMF)
Cryopyrin-associated Periodic Syndromes (CAPS)
TNF Receptor Associated Periodic Syndrome (TRAPS)
Hyper-IgD Syndrome / Mevalonate Kinase Deficiency (HIDS/MKD)
Systemic Juvenile Idiopathic Arthritis (sJIA)

Interventions: Biological: Ilaris

First Posted Date: 2025-02-20

Last Posted Date: 2025-03-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 16

Registration Number: NCT06838143

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy